Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

ABSTRACT:

Background

The efficacy and safety of nivolumab plus cabozantinib as compared with those of sunitinib in the treatment of previously untreated advanced renal-cell carcinoma are not known.

Methods

In this phase 3, randomized, open-label trial, we randomly assigned adults with previously untreated clear-cell, advanced renal-cell carcinoma to receive either nivolumab (240 mg every 2 weeks) plus cabozantinib (40 mg once daily) or sunitinib (50 mg once daily for 4 weeks of each 6-week cycle). The primary end point was progression-free survival, as determined by blinded independent central review. Secondary end points included overall survival, objective response as determined by independent review, and safety. Health-related quality of life was an exploratory end point.

Result

SUBMITTER: Choueiri TK 

PROVIDER: S-EPMC8436591 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature